Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (6): 572-577.DOI: 10.3969/j.issn.1673-8640.2018.06.022
Previous Articles Next Articles
YANG Jing, ZHU Linmin, CHEN Xingguo
Received:
2017-05-15
Online:
2018-06-30
Published:
2018-07-06
CLC Number:
YANG Jing, ZHU Linmin, CHEN Xingguo. Research progress in markers for the diagnosis of colorectal cancer[J]. Laboratory Medicine, 2018, 33(6): 572-577.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.06.022
[1] | SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2015[J]. CA Cancer J Clin,2015,65(1):5-29. |
[2] | 赵平,陈万青. 2010年中国肿瘤登记年报:中国肿瘤登记地区2007年癌症发病和死亡 [M]. 北京:军事医学科学出版社,2010:48-50. |
[3] | BENSON V S,PATNICK J,DAVIES A K,et al.Colorectal cancer screening:a comparison of 35 initiatives in 17 countries[J]. Int J Cancer,2008,122(6):1357-1367. |
[4] | 吴鹏,李艳,陈进,等. 联合免疫法和化学法检测粪便隐血的临床应用评价[J]. 检验医学,2010,25(3):176-178. |
[5] | VILKIN A,ROZEN P,LEVI Z,et al.Performance characteristics and evaluation of an automated-developed and quantitative,immunochemical,fecal occult blood screening test[J]. Am J Gastroenterol,2005,100(11):2519-2525. |
[6] | 龚学军. CEA 及CK20的不同检测方法对结直肠癌诊断及预后评估的初步探讨[D]. 长沙:中南大学,2010. |
[7] | WANG W S,LIN J K,CHIOU T J,et al.CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer[J]. Hepatogastroenterology,2002,49(43):160-164. |
[8] | 刘琳,张养民. 血清多种肿瘤标志物联合检测对结直肠癌的诊断价值[J]. 实用癌症杂志,2016,31(6):976-978. |
[9] | MAZUREK S,BOSCHEK C B,HUGO F,et al.Pyruvate kinase type M2 and its role in tumor growth and spreading[J]. Semin Cancer Biol,2005,15(4):300-308. |
[10] | SCHNEIDER J,SCHULZE G.Comparison of tumor M2-pyruvate kinase(tumor M2-PK),carcinoembryonic antigen(CEA),carbohydrate antigens CA19-9 and CA72-4 in the diagnosis of gastrointestinal cancer[J]. Anticancer Res,2003,23(6D):5089-5093. |
[11] | 喻鑫,刘弋. tM2-PK蛋白在结直肠癌中的表达及临床意义[J]. 安徽医科大学学报,2014,49(2):236-239. |
[12] | 杨刚,唐丽娟. 血清TuM2-PK、CEA、CA19-9和CA72-4对结肠癌的筛查价值[J]. 检验医学与临床,2017,14(1):35-36. |
[13] | 曾龙飞,田刚,姚健. Logistic回归和PLS-DA模型评价肿瘤标志物对结肠癌的诊断价值[J]. 重庆医学,2017,46(8):1038-1041. |
[14] | VOGEL T,DRIEMEL C,HAUSER A,et al.Comparison of different stool tests for the detection of cancer of the colon[J]. Dtsch Med Wochenschr,2005,130(14):872-877. |
[15] | HARDT P D,MAZUREK S,TOEPLER M,et al.Faecal tumour M2 pyruvate kinase:a new,sensitive screening tool for colorectal cancer[J]. Br J Cancer,2004,91(5):980-984. |
[16] | 梁钢,肖虹,郑绘霞,等. 粪便肿瘤M2型丙酮酸激酶检测对结直肠癌诊断价值的Meta分析[J]. 中华肿瘤防治杂志,2013,20(20):1607-1611. |
[17] | NAUMANN M,SCHAUM B,OREMEK G M,et al.Faecal pyruvate kinase type M2-a valid screening parameter for colorectal cancer?Preliminary results from a multicenter comparative study[J]. Dtsch Med Wochenschr,2004,129(34-35):1806-1807. |
[18] | 张虎,朱尤庆,吴亚琼,等. 粪便基因甲基化对结直肠肿瘤诊断价值的Meta分析[J]. 中国循证医学杂志,2013,13(2):149-159. |
[19] | COPPEDÈ F.Epigenetic biomarkers of colorectal cancer:focus on DNA methylation[J]. Cancer Lett,2014,342(2):238-247. |
[20] | WARREN J D,XIONG W,BUNKER A M,et al.Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer[J]. BMC Med,2011,9:133. |
[21] | TÓTH K,SIPOS F,KALMÁR A,et al. Detection of methylated SEPT 9 plasma is a reliable screening method for both left- and right- sided colon cancers[J]. PLoS One,2012,7(9):e46000. |
[22] | GRÜTZMANN R,MOLNAR B,PILARSKY C,et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay[J]. PLoS one,2008,3(11):e3759. |
[23] | CHURCH T R,WANDELL M,LOFTON-DAY C,et al.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut,2014,63(2):317-325. |
[24] | LEE H S,HWANG S M,KIM T S,et al.Circulating methylated septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon[J]. Transl Oncol,2013,6(3):290-296. |
[25] | DOMINIC O G,MCGARRITY T,DIGNAN M,et al.American College of Gastroenterology guidelines for colorectal cancer screening 2008[J]. Am J Gastroenterol,2009,104(10):2626-2627. |
[26] | LI M,CHEN W D,PAPADOPOULOS N,et al.Sensitive digital quantification of DNA methylation in clinical samples[J]. Nat Biotechnol,2009,27(9):858-863. |
[27] | WANG D R,TANG D.Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening[J]. World J Gastroenterol,2008,14(4):524-531. |
[28] | MELOTTE V,LENTJES M H,VAN DEN BOSCH S M,et al. N-Myc downstream-regulated gene 4(NDRG4):a candidate tumor suppressor gene and potential biomarker for colorectal cancer[J]. J Natl Cancer Inst,2009,101(13):916-927. |
[29] | AHLQUIST D A.Molecular detection of colorectal neoplasia[J]. Gastroenterology,2010,138(6):2127-2139. |
[30] | CHEN C,RIDZON D A,BROOMER A J,et al.Real-time quantification of microRNAs by stem-loop RT-PCR[J]. Nucleic Acids Res,2005,33(20):e179. |
[31] | CHEN X,BA Y,MA L,et al.Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res,2008,18(10):997-1006. |
[32] | NG E K,CHONG W W,JIN H,et al.Differential expression of microRNAs in plasma of patients with colorectal cancer:a potential marker for colorectal cancer screening[J]. Gut,2009,58(10):1375-1381. |
[33] | HUANG Z,HUANG D,NI S,et al.Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer[J]. Int J Cancer,2010,127(1):118-126. |
[34] | KANAAN Z,RAI S N,EICHENBERGER M R,et al.Plasma miR-21:a potential diagnostic marker of colorectal cancer[J]. Ann Surg,2012,256(3):544-551. |
[35] | HOLLIS M,NAIR K,VYAS A,et al.MicroRNAs potential utility in colon cancer:early detection,prognosis and chemosensitivity[J]. World J Gastroenterol,2015,21(27):8284-8292. |
[36] | WU C W,NG S S,DONG Y J,et al.Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps[J]. Gut,2012,61(5):739-745. |
[37] | LI J M,ZHAO R H,LI S T,et al.Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer[J]. Saudi Med J,2012,33(1):24-29. |
[38] | ZHU Y,XU A,LI J,et al.Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer[J]. Cancer Biomark,2016,16(2):259-264. |
[39] | GHANBARI R,MOSAKHANI N,ASADI J,et al.Decreased expression of fecal miR-4478 and miR-1295b-3p in early-stage colorectal cancer[J]. Cancer Biomark,2015,15(2):189-195. |
[40] | 钟武,张磊昌,钟世彪,等. 结直肠癌粪便miRNA-21的表达及其临床意义[J]. 结直肠肛门外科,2015,21(2):95-98. |
[41] | MAZEH H,MIZRAHI I,ILYAYEV N,et al.The diagnostic and prognostic role of microRNA in colorectal cancer-a comprehensive review[J]. J Cancer,2013,4(3):281-295. |
[42] | 薛亚晶,陈建,张金业,等. 粪便微RNA-141、-17-3p和-92a-3p对结直肠癌诊断及预后判断的价值[J]. 肿瘤,2016,36(8):901-907. |
[1] | LI Liangshan, ZHAO Hu, WANG Shiwen. Screening potential prognostic biomarkers of colorectal cancer based on weighted gene co-expression network analysis [J]. Laboratory Medicine, 2023, 38(9): 825-832. |
[2] | CHEN Wenju, ZHOU Yong, XU Jiajia, WANG Pan. Role of serum exosomal miR-23b-3p and miR-4429 in patients with hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 624-628. |
[3] | ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer [J]. Laboratory Medicine, 2023, 38(7): 629-633. |
[4] | PAN Xin, LÜ Ying, LI Yang, LI Rongguo. Effects of miR-24-3p targeting CHD5 on migration,invasion and radiosensitivity of thyroid cancer cells [J]. Laboratory Medicine, 2023, 38(7): 640-646. |
[5] | WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691. |
[6] | ZHANG Ying, JING Lijuan, LI Li. Relationship between the expression of miR-138 in peripheral blood mononuclear cells of hepatitis B virus proliferation in carriers [J]. Laboratory Medicine, 2023, 38(6): 559-562. |
[7] | ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418. |
[8] | GAO Feng. Clinical application of novel tumor biomarkers:prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306. |
[9] | JIANG Mengying, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, DU Yan. Clinical role of serum S1P in the early diagnosis of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 307-312. |
[10] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319. |
[11] | LIU Ruili, LI Lanjun, JIA Minlei, WANG Yihui, HAO Weina. Correlation between tumor miR-7-5p and NOVA2 levels and clinical prognosis in cancer tissues of patients with gastric cancer [J]. Laboratory Medicine, 2023, 38(4): 325-329. |
[12] | YANG Jielin, WANG Xiaoyuan, LI Haixia. Expression and interaction of TRX and TXNIP in colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 330-336. |
[13] | YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341. |
[14] | CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256. |
[15] | LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||